- Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;
【Abstract】ObjectiveTo investigate the relationship between galectin-3 and tumour metastasis, and the future prospect of galectin-3 in clinic.
MethodsRelated articles were reviewed.
ResultsGalectin-3, a member of the β-galactoside-binding proteins, is expressed widely in epithelial and immune cells, and interacts with intracellular glycoproteins, cell surface molecules and extracellular matrix proteins. Galectin-3 is involved in various biological phenomena including cell growth, adhesion, differentiation, angiogenesis and apoptosis, and is associated with invasion and metastasis of tumour.
ConclusionBecause of the correlation between galectin-3 and tumour invasion and metastasis, galectin-3 may act as the diagnostic marker for tumour metastasis and one of the target proteins for cancer treatment.
Citation: YANG Zhiming,WU Xiaoting,HE Tao.. Galectin-3 and Tumour Metastasis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2005, 12(3): 310-313. doi: Copy
1. | Liu FT, Hsu DK, Zuberi RI, et al. Expression and function of galectin3, a betagalactosidebinding lectin, in human monocytes and macrophages [J]. Am J Pathol, 1995; 147(4)∶1016. |
2. | Lotan R, Ito H, Yasui W, et al. Expression of a 31kDa lactosidebinding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas [J]. Int J Cancer, 1994; 56(4)∶474. |
3. | Nagy N, Legendre H, Engels O, et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting [J]. Cancer, 2003; 97(8)∶1849. |
4. | Schoeppner HL, Raz A, Ho SB, et al. Expression of an endogenous galactosebinding lectin correlates with neoplastic progression in the colon [J]. Cancer, 1995; 75(12)∶2818. |
5. | O’Driscoll L, Linehan R, MKennedy S, et al. Lack of prognostic significance of survivin, survivindeltaEx3, survivin2B, galectin3, bag1, baxalpha and MRP1 mRNAs in breast cancer [J]. Cancer Lett, 2003; 201(2)∶225. |
6. | Ellerhorst JA, Stephens LC, Nguyen T, et al. Effects of galectin3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP [J]. Prostate, 2002; 50(1)∶64. |
7. | Konstantinov KN, Robbins BA, Liu FT. Galectin3, a betagalactosidebinding animal lectin, is a marker of anaplastic largecell lymphoma [J]. Am J Pathol, 1996; 148(1)∶25. |
8. | Xu XC, elNaggar AK, Lotan R. Differential expression of galectin1 and galectin3 in thyroid tumors. Potential diagnostic implications [J]. Am J Pathol, 1995; 147(3)∶815. |
9. | van den Brule FA, Buicu C, Berchuck A, et al. Expression of the 67kD laminin receptor, galectin1, and galectin3 in advanced human uterine adenocarcinoma [J]. Hum Pathol, 1996; 27(11)∶1185. |
10. | Mollenhauer J, Deichmann M, Helmke B, et al. Frequent downregulation of DMBT1 and galectin3 in epithelial skin cancer [J]. Int J Cancer, 2003; 105(2)∶149. |
11. | Gillenwater A, Xu XC, elNaggar AK, et al. Expression of galectins in head and neck squamous cell carcinoma [J]. Head Neck, 1996; 18(5)∶422. |
12. | Baldus SE, Zirbes TK, Weingarten M, et al. Increased galectin3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation [J]. Tumour Biol, 2000; 21(5)∶258. |
13. | Woo HJ, Joo HG, Song SW, et al. Immunohistochemical detection of galectin3 in canine gastric carcinomas [J]. J Comp Pathol, 2001; 124(2-3)∶216. |
14. | Barondes SH, Cooper DN, Gitt MA, et al. Galectins. Structure and function of a large family of animal lectins [J]. J Biol Chem, 1994;269(33)∶20807. |
15. | Gong HC, Honjo Y, NangiaMakker P, et al. The NH2 terminus of galectin3 governs cellular compartmentalization and functions in cancer cells [J]. Cancer Res, 1999; 59(24)∶6239. |
16. | Herrmann J, Turck CW, Atchison RE, et al. Primary structure of the soluble lactose binding lectin L29 from rat and dog and interaction of its noncollagenous proline, glycine, tyrosinerich sequence with bacterial and tissue collagenase [J]. J Biol Chem, 1993; 268(35)∶26704. |
17. | Kohn EC. Development and prevention of metastasis [J]. Anticancer Res, 1993; 13(6B)∶2553. |
18. | Raz A, Lotan R. Endogenous galactosidebinding lectins: a new class of functional tumor cell surface molecules related to metastasis [J]. Cancer Metastasis Rev, 1987; 6(3)∶433. |
19. | Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995; 1(1)∶27. |
20. | NangiaMakker P, Baccarini S, Raz A. Carbohydraterecognition and angiogenesis [J]. Cancer Metastasis Rev, 2000; 19(1-2)∶51. |
21. | Moiseeva EP, Javed Q, Spring EL, et al. Galectin 1 is involved in vascular smooth muscle cell proliferation [J]. Cardiovasc Res, 2000; 45(2)∶493. |
22. | NangiaMakker P, Honjo Y, Sarvis R, et al. Galectin3 induces endothelial cell morphogenesis and angiogenesis [J]. Am J Pathol, 2000; 156(3)∶899. |
23. | Woo HJ, Shaw LM, Messier JM, et al. The major nonintegrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac2) [J]. J Biol Chem, 1990; 265(13)∶7097. |
24. | Parise LV, Lee J, Juliano RL. New aspects of integrin signaling in cancer [J]. Semin Cancer Biol, 2000; 10(6)∶407. |
25. | Matarrese P, Fusco O, Tinari N, et al. Galectin3 overexpression protects from apoptosis by improving cell adhesion properties [J]. Int J Cancer, 2000; 85(4)∶545. |
26. | Warfield PR, Makker PN, Raz A, et al. Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin3 [J]. Invasion Metastasis, 1997; 17(2)∶101. |
27. | Ochieng J, Fridman R, NangiaMakker P, et al. Galectin3 is a novel substrate for human matrix metalloproteinases2 and 9 [J]. Biochemistry, 1994; 33(47)∶14109. |
28. | Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment [J]. Oncogene, 2000; 19(56)∶6642. |
29. | Raz A, Bucana C, McLellan W, et al. Distribution of membrane anionic sites on B16 melanoma variants with differing lung colonising potential [J]. Nature, 1980; 284(5754)∶363. |
30. | Inohara H, Akahani S, Koths K, et al. Interactions between galectin3 and Mac2binding protein mediate cellcell adhesion [J]. Cancer Res, 1996; 56(19)∶4530. |
31. | Glinsky VV, Huflejt ME, Glinsky GV, et al. Effects of ThomsenFriedenreich antigenspecific peptide P30 on betagalactosidemediated homotypic aggregation and adhesion to the endothelium of MDAMB435 human breast carcinoma cells [J]. Cancer Res, 2000; 60(10)∶2584. |
32. | Glinsky VV, Glinsky GV, RittenhouseOlson K, et al. The role of ThomsenFriedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium [J]. Cancer Res, 2001; 61(12)∶4851. |
33. | Mareel MM, Crombez R. Biology of cancer invasion and metastasis [J]. Acta Otorhinolaryngol Belg, 1992; 46(2)∶107. |
34. | Zhu Z, SanchezSweatman O, Huang X, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells [J]. Cancer Res, 2001; 61(4)∶1707. |
35. | Kim HR, Lin HM, Biliran H, et al. Cell cycle arrest and inhibition of anoikis by galectin3 in human breast epithelial cells [J]. Cancer Res, 1999; 59(16)∶4148. |
36. | Yoshii T, Fukumori T, Honjo Y, et al. Galectin3 phosphorylation is required for its antiapoptotic function and cell cycle arrest [J]. J Biol Chem, 2002; 277(9)∶6852. |
37. | Akahani S, NangiaMakker P, Inohara H, et al. Galectin3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl2 family [J]. Cancer Res, 1997; 57(23)∶5272. |
38. | Iurisci I, Tinari N, Natoli C, et al. Concentrations of galectin3 in the sera of normal controls and cancer patients [J]. Clin Cancer Res, 2000; 6(4)∶1389. |
39. | Platt D, Raz A. Modulation of the lung colonization of B16F1 melanoma cells by citrus pectin [J]. J Natl Cancer Inst, 1992; 84(6)∶438. |
40. | NangiaMakker P, Honjo Y, Sarvis R, et al. Galectin3 induces endothelial cell morphogenesis and angiogenesis [J]. Am J Pathol, 2000; 156(3)∶899. |
41. | NangiaMakker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin [J]. J Natl Cancer Inst, 2002; 94(24)∶1854. |
42. | Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin [J]. J Natl Cancer Inst, 1995; 87(5)∶348. |
43. | Colnot C, Fowlis D, Ripoche MA, et al. Embryonic implantation in galectin 1/galectin 3 double mutant mice [J]. Dev Dyn, 1998; 211(4)∶306. |
- 1. Liu FT, Hsu DK, Zuberi RI, et al. Expression and function of galectin3, a betagalactosidebinding lectin, in human monocytes and macrophages [J]. Am J Pathol, 1995; 147(4)∶1016.
- 2. Lotan R, Ito H, Yasui W, et al. Expression of a 31kDa lactosidebinding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas [J]. Int J Cancer, 1994; 56(4)∶474.
- 3. Nagy N, Legendre H, Engels O, et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting [J]. Cancer, 2003; 97(8)∶1849.
- 4. Schoeppner HL, Raz A, Ho SB, et al. Expression of an endogenous galactosebinding lectin correlates with neoplastic progression in the colon [J]. Cancer, 1995; 75(12)∶2818.
- 5. O’Driscoll L, Linehan R, MKennedy S, et al. Lack of prognostic significance of survivin, survivindeltaEx3, survivin2B, galectin3, bag1, baxalpha and MRP1 mRNAs in breast cancer [J]. Cancer Lett, 2003; 201(2)∶225.
- 6. Ellerhorst JA, Stephens LC, Nguyen T, et al. Effects of galectin3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP [J]. Prostate, 2002; 50(1)∶64.
- 7. Konstantinov KN, Robbins BA, Liu FT. Galectin3, a betagalactosidebinding animal lectin, is a marker of anaplastic largecell lymphoma [J]. Am J Pathol, 1996; 148(1)∶25.
- 8. Xu XC, elNaggar AK, Lotan R. Differential expression of galectin1 and galectin3 in thyroid tumors. Potential diagnostic implications [J]. Am J Pathol, 1995; 147(3)∶815.
- 9. van den Brule FA, Buicu C, Berchuck A, et al. Expression of the 67kD laminin receptor, galectin1, and galectin3 in advanced human uterine adenocarcinoma [J]. Hum Pathol, 1996; 27(11)∶1185.
- 10. Mollenhauer J, Deichmann M, Helmke B, et al. Frequent downregulation of DMBT1 and galectin3 in epithelial skin cancer [J]. Int J Cancer, 2003; 105(2)∶149.
- 11. Gillenwater A, Xu XC, elNaggar AK, et al. Expression of galectins in head and neck squamous cell carcinoma [J]. Head Neck, 1996; 18(5)∶422.
- 12. Baldus SE, Zirbes TK, Weingarten M, et al. Increased galectin3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation [J]. Tumour Biol, 2000; 21(5)∶258.
- 13. Woo HJ, Joo HG, Song SW, et al. Immunohistochemical detection of galectin3 in canine gastric carcinomas [J]. J Comp Pathol, 2001; 124(2-3)∶216.
- 14. Barondes SH, Cooper DN, Gitt MA, et al. Galectins. Structure and function of a large family of animal lectins [J]. J Biol Chem, 1994;269(33)∶20807.
- 15. Gong HC, Honjo Y, NangiaMakker P, et al. The NH2 terminus of galectin3 governs cellular compartmentalization and functions in cancer cells [J]. Cancer Res, 1999; 59(24)∶6239.
- 16. Herrmann J, Turck CW, Atchison RE, et al. Primary structure of the soluble lactose binding lectin L29 from rat and dog and interaction of its noncollagenous proline, glycine, tyrosinerich sequence with bacterial and tissue collagenase [J]. J Biol Chem, 1993; 268(35)∶26704.
- 17. Kohn EC. Development and prevention of metastasis [J]. Anticancer Res, 1993; 13(6B)∶2553.
- 18. Raz A, Lotan R. Endogenous galactosidebinding lectins: a new class of functional tumor cell surface molecules related to metastasis [J]. Cancer Metastasis Rev, 1987; 6(3)∶433.
- 19. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995; 1(1)∶27.
- 20. NangiaMakker P, Baccarini S, Raz A. Carbohydraterecognition and angiogenesis [J]. Cancer Metastasis Rev, 2000; 19(1-2)∶51.
- 21. Moiseeva EP, Javed Q, Spring EL, et al. Galectin 1 is involved in vascular smooth muscle cell proliferation [J]. Cardiovasc Res, 2000; 45(2)∶493.
- 22. NangiaMakker P, Honjo Y, Sarvis R, et al. Galectin3 induces endothelial cell morphogenesis and angiogenesis [J]. Am J Pathol, 2000; 156(3)∶899.
- 23. Woo HJ, Shaw LM, Messier JM, et al. The major nonintegrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac2) [J]. J Biol Chem, 1990; 265(13)∶7097.
- 24. Parise LV, Lee J, Juliano RL. New aspects of integrin signaling in cancer [J]. Semin Cancer Biol, 2000; 10(6)∶407.
- 25. Matarrese P, Fusco O, Tinari N, et al. Galectin3 overexpression protects from apoptosis by improving cell adhesion properties [J]. Int J Cancer, 2000; 85(4)∶545.
- 26. Warfield PR, Makker PN, Raz A, et al. Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin3 [J]. Invasion Metastasis, 1997; 17(2)∶101.
- 27. Ochieng J, Fridman R, NangiaMakker P, et al. Galectin3 is a novel substrate for human matrix metalloproteinases2 and 9 [J]. Biochemistry, 1994; 33(47)∶14109.
- 28. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment [J]. Oncogene, 2000; 19(56)∶6642.
- 29. Raz A, Bucana C, McLellan W, et al. Distribution of membrane anionic sites on B16 melanoma variants with differing lung colonising potential [J]. Nature, 1980; 284(5754)∶363.
- 30. Inohara H, Akahani S, Koths K, et al. Interactions between galectin3 and Mac2binding protein mediate cellcell adhesion [J]. Cancer Res, 1996; 56(19)∶4530.
- 31. Glinsky VV, Huflejt ME, Glinsky GV, et al. Effects of ThomsenFriedenreich antigenspecific peptide P30 on betagalactosidemediated homotypic aggregation and adhesion to the endothelium of MDAMB435 human breast carcinoma cells [J]. Cancer Res, 2000; 60(10)∶2584.
- 32. Glinsky VV, Glinsky GV, RittenhouseOlson K, et al. The role of ThomsenFriedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium [J]. Cancer Res, 2001; 61(12)∶4851.
- 33. Mareel MM, Crombez R. Biology of cancer invasion and metastasis [J]. Acta Otorhinolaryngol Belg, 1992; 46(2)∶107.
- 34. Zhu Z, SanchezSweatman O, Huang X, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells [J]. Cancer Res, 2001; 61(4)∶1707.
- 35. Kim HR, Lin HM, Biliran H, et al. Cell cycle arrest and inhibition of anoikis by galectin3 in human breast epithelial cells [J]. Cancer Res, 1999; 59(16)∶4148.
- 36. Yoshii T, Fukumori T, Honjo Y, et al. Galectin3 phosphorylation is required for its antiapoptotic function and cell cycle arrest [J]. J Biol Chem, 2002; 277(9)∶6852.
- 37. Akahani S, NangiaMakker P, Inohara H, et al. Galectin3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl2 family [J]. Cancer Res, 1997; 57(23)∶5272.
- 38. Iurisci I, Tinari N, Natoli C, et al. Concentrations of galectin3 in the sera of normal controls and cancer patients [J]. Clin Cancer Res, 2000; 6(4)∶1389.
- 39. Platt D, Raz A. Modulation of the lung colonization of B16F1 melanoma cells by citrus pectin [J]. J Natl Cancer Inst, 1992; 84(6)∶438.
- 40. NangiaMakker P, Honjo Y, Sarvis R, et al. Galectin3 induces endothelial cell morphogenesis and angiogenesis [J]. Am J Pathol, 2000; 156(3)∶899.
- 41. NangiaMakker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin [J]. J Natl Cancer Inst, 2002; 94(24)∶1854.
- 42. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin [J]. J Natl Cancer Inst, 1995; 87(5)∶348.
- 43. Colnot C, Fowlis D, Ripoche MA, et al. Embryonic implantation in galectin 1/galectin 3 double mutant mice [J]. Dev Dyn, 1998; 211(4)∶306.